Gene Therapy to Promulgate Oligonucleotide APIs Market - Study

Jul 17,2020 | Healthcare

According to FMI – an ESOMAR-certified market research firm, the global oligonucleotide API market is estimated to reach US$ 3 Bn in 2020, and witness a CAGR of 11% through 2030.

Oligonucleotide Api Market

A recent market study published by Future Market Insights (FMI) on the Oligonucleotide API...

Oligonucleotide Api Market

According to FMI’s analysis, as of now, 100+ oligonucleotide APIs are in the clinical trials’ phase, and regulatory approval is on the cards. Post-approval, the demand for production capacity will witness an exponentiation, thereby driving the oligonucleotide API market through 2030.

Oligonucleotides are being looked upon as the subsequent large group of therapeutics following biologics and molecules. This could be attributed to the assurance on their part to develop drugs at lower costs.

Apart from immune therapy, microbial and cardiovascular infections, and cancer, oligonucleotide APIs are being tried out to treat neurological disorders like Alzheimer’s as well. However, factors like regulatory complexities and timely delivery of oligonucleotides (amidst Covid-19) are acting as restraints.

Key Takeaways from Oligonucleotide API Marker Study

  • Antisense Oligonucleotides APIs are anticipated to reach US$ 4 Bn by 2030.
  • North America and Europe collectively accounted for more than 47% of revenue share in 2019 while Asia Pacific is expected to grow at the fastest rate in the forecast period.
  • Increase in use of antisense oligonucleotide APIs (especially post approval from US FDA in 2016) to boost the market in the forecast period

New Product Launches: Key Indicators to Oligonucleotide APIs Market

FMI has analyzed players such as Akcea Therapeutics, Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Dynavax Technologies in this report. According to the analysis, these players are consolidating their positions through new product launches.

For instance –

  • In Mar 2020, Dynavax entered into collaboration with Clover Biopharmaceuticals for developing a vaccine candidate to combat Covid-19. Clover is into advanced evaluation of its Covid-19 S-Trimer, protein-based coronavirus vaccine candidate and Dynavax has its technical expertise along with proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018 for executing this.
  • Alnylam Pharmaceuticals, Inc., in 2018, launched Givlaari and Onpattro at the commercial level.

"Inorganic mode of growth coupled with broad therapeutic applications in gene therapy is expected to bolster the oligonucleotide API market” says the FMI analyst.

Gene Therapy and Oligonucleotide APIs

Synthetic oligonucleotides are being used in gene therapy for inactivating genes that help in propagating the disease. Antisense oligonucleotide APIs are used for disrupting the faulty gene’s transcription.

Also, siRNA could be used for signaling the cell to disrupt faulty mRNA’s translation. Along these lines, Pharmamar, in Jan 2020, signed an agreement with Jazz Pharmaceuticals for selling the API for “lurbinectedin”, one of the late-phase treatments for SCLC (small cell lung cancer) so that the latter could commercialize it.

Want more insights?

The study provides compelling insights on Oligonucleotide API market on basis of API type in detail cover every aspects of the market such as Antisense Oligonucleotides API, Short Interfering RNA (siRNA) API, Phosphorodiamidate Morpholino Oligonucleotides (PMO) API, MiRNA API, Aptamers API, CpG Oligonucleotides API  and Others (ON Conjugates (NP), ShRNA, etc.), Marketing Status (Marketed, Clinical Trials (Clinical Phases)), and end users (Pharmaceutical Companies  and Biotechnology Companies)) across seven major regions. 

About the Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.